Cellectis (CLLS) Tops Q3 EPS by 26c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Cellectis (CLLS) Tops Q3 EPS by 26c

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019

November 6, 2019 4:47 PM EST

First patient dosed with UCARTCS1 in MELANI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory Multiple Myeloma Patient screening ongoing with UCART22 in BALLI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Grant of a new IND for UCART123 following a change in production process and site initiation ongoing for AMELI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory Acute Myeloid Leukemia Francisco Esteva, M.D., Ph.D., joined team as Vice President, Clinical Development Milestone... More